Breast Cancer

NCCN Clinical Practice Guidelines in Oncology: 2020 Updates Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.

Go to full news story published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid Tumors Bookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Breast Cancer—An Overview Bookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

Breast cancer is the most common potentially lethal cancer diagnosed among American women. The great majority are cured, but that does not mean that the topic is without disagreements. To learn more, read this authoritative, up-to-date, detailed presentation from Medscape.

. 

Atezolizumab/Nab-Paclitaxel Approved by the FDA for PD-L1+ TNBC Bookmark

Excerpt:

“An accelerated approval has been granted by the FDA for the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a frontline treatment for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).

“The approval is based on the phase III IMpassion130 trial, in which the addition of the PD-L1 inhibitor atezolizumab to nab-paclitaxel reduced the risk of progression or death by 40% compared with nab-paclitaxel alone in this patient population.”

Go to full article published by Targeted Oncology on March 8, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer Bookmark

Excerpt:

“On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.

“Approval was based on EMBRACA (NCT01945775), an open‑label trial randomizing 431 patients (2:1) with gBRCAm HER2‑negative locally advanced or metastatic breast cancer to receive talazoparib (1 mg) or physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). All patients were required to have a known deleterious or suspected deleterious gBRCA mutation and must have received no more than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease. Patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant, and/or metastatic treatment setting.”

Go to full article published by the U.S. Food and Drug Administration on Oct 16, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Biomarker Testing for Cancer Treatment Bookmark

Each person with cancer has unique biomarkers that may determine how well specific treatments might work for them. Learn more from this website all about biomarkers, prepared by the National Cancer Institute.

.

Experimental Drug Helps Women With Deadly Type of Breast Cancer Bookmark

Excerpt:

“An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.

“Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.”

Go to full article published by U.S. News on Feb 20, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

NCI-Supported Clinical Trials for Coronavirus Bookmark

This list from the National Cancer Institute outlines many government-supported clinical trials for COVID-19 that may be specifically for cancer survivors.

.